Transition to Rebif New Formulation

2014-08-26 22:32:50 | BioPortfolio

Summary

To assess patient satisfaction with respect to the incidence of flu-like symptoms in patients with multiple sclerosis transitioned from current Rebif (subcutaneously injected interferon beta-1a, 44mcg three-times-weekly) to the new formulation of Rebif while receiving ibuprofen either prophylactically or only when necessary (PRN) after the occurance of flu-like symptoms.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Conditions

Relapsing Multiple Sclerosis

Intervention

Rebif New Formulation + prophylactically Ibuprofen, Rebif New Formulation + ibuprofen PRN

Location

Local Medical Information
Paris
France

Status

Completed

Source

EMD Serono

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-26T22:32:50-0400

Clinical Trials [1139 Associated Clinical Trials listed on BioPortfolio]

Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)

The rationale of this study is to assess the safety profile, efficacy and adherence to Rebif® New Formulation in real life settings with a multinational approach, as well as the impact of...

REbif FLEXible Dosing in Early Multiple Sclerosis (MS)

The primary objective of the study is to evaluate the effect of Rebif New Formulation 44 mcg (tiw and ow) versus placebo on the time to conversion to McDonald MS in patients with a first c...

Study Comparing the Efficacy ofTwo Ibuprofen Formulations

This is a study of healthy volunteers to compare how quickly different ibuprofen products relieve dental pain.

Study Evaluating a Novel Ibuprofen Formulation in the Treatment of Dental Pain

This study will compare the analgesic efficacy of a single-dose of a novel ibuprofen formulation to placebo and two formulations of standard ibuprofen in the treatment of post-surgical den...

Pharmacokinetics of 3 Formulations of Ibuprofen Suppositories

The purpose of this study is to compare the pharmacokinetic and bioavailability characteristics of two test formulations of ibuprofen for rectal administration with the profile of a market...

PubMed Articles [1160 Associated PubMed Articles listed on BioPortfolio]

Experimental and chemoinformatics evaluation of some physicochemical properties of excipients influencing release kinetics of the acidic drug ibuprofen.

In the present study, ibuprofen, a nonsteroidal anti-inflammatory drug was used in the formulation of tablets using three polymers representing different categories (immediate, moderate and extended r...

Application of β-Cyclodextrin in the Formulation of ODT Tablets Containing Ibuprofen.

Oral disintegrating tablet (ODT) dissolves or disintegrates in saliva and then it is swallowed. Diluent in direct compression formulation has a dual role: it increases bulk of the dosage form and it p...

Formulation studies on ibuprofen sodium-cationic dextran conjugate: effect on tableting and dissolution characteristics of ibuprofen.

The effect of electrostatic interaction between ibuprofen sodium (IbS) and cationic diethylaminoethyl dextran (Ddex), on the tableting properties and ibuprofen release from the conjugate tablet was in...

Ibuprofen-in-cyclodextrin-in-W/O/W emulsion - Improving the initial and long-term encapsulation efficiency of a model active ingredient.

A challenge in formulating water-in-oil-in-water (W/O/W) emulsions is the uncontrolled release of the encapsulated compound prior to application. Pharmaceuticals and nutraceuticals usually have amphip...

Timing of Ibuprofen Use and Musculoskeletal Adaptations to Exercise Training in Older Adults.

Prostaglandins (PG) increase in bone in response to mechanical loading and stimulate bone formation. Inhibition of cyclooxygenase (COX), the enzyme responsible for PG synthesis, by non-steroidal anti-...

Medical and Biotech [MESH] Definitions

A nonsteroidal anti-inflammatory agent with analgesic properties used in the therapy of rheumatism and arthritis.

An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.

An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic.

Disorders in which phagocytic cells cannot kill ingested bacteria; characterized by frequent recurring infection with formulation of granulomas.

A field of biological research combining engineering in the formulation, design, and building (synthesis) of novel biological structures, functions, and systems.

More From BioPortfolio on "Transition to Rebif New Formulation"


Advertisement
 

Relevant Topic

Multiple Sclerosis MS
Latest News Clinical Trials Research Drugs Reports Corporate
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...

Advertisement
 

Searches Linking to this Trial